ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
Dow Jones
38,798.99
-0.22%
US Dollar vs MXN
18.4136
0.00%
Brent Oil
79.395
0.00%
Bitcoin
69,359.63
0.04%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Zevra Therapeutics Inc (ZVRA)

  7. Zevra Therapeutics Inc (ZVRA) Noticias

ZVRA

Zevra Therapeutics (ZVRA)

Zevra Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:ZVRA
FechaHoraFuenteTítuloSímboloCompañía
04/06/202416:13Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ZVRAZevra Therapeutics Inc
03/06/202410:00GlobeNewswire Inc.Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
15/05/202420:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
13/05/202415:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ZVRAZevra Therapeutics Inc
09/05/202415:34Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ZVRAZevra Therapeutics Inc
09/05/202406:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor EventsNASDAQ:ZVRAZevra Therapeutics Inc
08/05/202406:00GlobeNewswire Inc.Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
01/05/202406:30GlobeNewswire Inc.Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024NASDAQ:ZVRAZevra Therapeutics Inc
29/04/202406:30GlobeNewswire Inc.Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024NASDAQ:ZVRAZevra Therapeutics Inc
15/04/202416:01GlobeNewswire Inc.Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual MeetingNASDAQ:ZVRAZevra Therapeutics Inc
10/04/202406:30GlobeNewswire Inc.Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit FacilityNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202415:32GlobeNewswire Inc.Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate UpdatesNASDAQ:ZVRAZevra Therapeutics Inc
28/03/202406:42IH Market NewsUS Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices RiseNASDAQ:ZVRAZevra Therapeutics Inc
26/03/202415:30GlobeNewswire Inc.Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic HypersomniaNASDAQ:ZVRAZevra Therapeutics Inc
25/03/202415:30GlobeNewswire Inc.Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
18/03/202406:30GlobeNewswire Inc.Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024NASDAQ:ZVRAZevra Therapeutics Inc
04/03/202406:30GlobeNewswire Inc.Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
28/02/202406:30GlobeNewswire Inc.Zevra Therapeutics to Participate at Upcoming Investor ConferencesNASDAQ:ZVRAZevra Therapeutics Inc
14/02/202415:51Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ZVRAZevra Therapeutics Inc
06/02/202406:30GlobeNewswire Inc.Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ZVRAZevra Therapeutics Inc
02/02/202406:13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ZVRAZevra Therapeutics Inc
23/01/202406:30GlobeNewswire Inc.Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of DirectorsNASDAQ:ZVRAZevra Therapeutics Inc
11/01/202415:50Dow Jones NewsXoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for ArimoclomolNASDAQ:ZVRAZevra Therapeutics Inc
08/01/202406:30GlobeNewswire Inc.Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type CNASDAQ:ZVRAZevra Therapeutics Inc
04/01/202407:55GlobeNewswire Inc.Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical OfficerNASDAQ:ZVRAZevra Therapeutics Inc
27/12/202307:24Dow Jones NewsZevra Therapeutics Refiles Arimoclomol Application With FDANASDAQ:ZVRAZevra Therapeutics Inc
27/12/202306:30GlobeNewswire Inc.Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application to the U.S. Food and Drug AdministrationNASDAQ:ZVRAZevra Therapeutics Inc
20/11/202306:30GlobeNewswire Inc.Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease CompanyNASDAQ:ZVRAZevra Therapeutics Inc
07/11/202306:00GlobeNewswire Inc.Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial ResultsNASDAQ:ZVRAZevra Therapeutics Inc
31/10/202306:30GlobeNewswire Inc.Zevra Therapeutics to Report Third Quarter 2023 Results on November 7, 2023, at 8:00 a.m. ETNASDAQ:ZVRAZevra Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ZVRA

Su Consulta Reciente

BIT
S28938
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados